COMP <GO>
QTTB vs UNH // RETURN ON INVESTED CAPITAL (ROIC)
Q32 Bio Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: QTTB 6
— UNH 5
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: QTTB
LAST: $8.87 (-2.10%) • MKT CAP: $264.1M
roic
85.00%
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
roic
11.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QTTB VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | QTTB | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.57% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 85.00% | 11.47% | +73.53 | QTTB | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.8x | 16.4x | -3.65 | QTTB | /valuation <GO> |
| Free Cash Flow Yield | -12.70% | 6.48% | -19.18 | UNH | /fcf-yield <GO> |
| Operating Margin | 31.50% | 4.82% | +26.68 | QTTB | /operating-margins <GO> |
| Net Profit Margin | 55.50% | 3.14% | +52.36 | QTTB | /net-margins <GO> |
| Revenue Growth (YoY) | — | 6.46% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.99 | 3.12 | +2.87 | QTTB | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.1 | 59.2 | -11.08 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.3x | 17.1x | -8.79 | QTTB | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $264.1M | $368.83B | -$368.57B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | QTTB REV | UNH REV | QTTB GROSS % | UNH GROSS % | QTTB FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $53.7M | $447.57B | — | 88.7% | -$33.5M | $16.07B |
| FY 2024 | $0 | $400.28B | — | 88.3% | -$67.8M | $20.70B |
| FY 2023 | $1.2M | $371.62B | — | 89.6% | -$18.7M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QTTB // BETA —
UNH // BETA 0.33